Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Santhera Pharmaceuticals
Santhera Pharmaceuticals
Duchenne muscular dystrophy’s progress so far in 2023
Duchenne muscular dystrophy’s progress so far in 2023
Clinical Trials Arena
Duchenne Muscular Dystrophy
DMD
Santhera Pharmaceuticals
ReveraGen
vamorolone
Regenxbio
RGX-202
Flag link:
FDA accepts Santhera, ReveraGen’s vamorolone NDA to treat DMD
FDA accepts Santhera, ReveraGen’s vamorolone NDA to treat DMD
Pharmaceutical Business Review
Santhera Pharmaceuticals
ReveraGen
vamorolone
Duchenne Muscular Dystrophy
FDA
Flag link:
Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Endpoints
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy
vamorolone
clinical trials
Flag link:
Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application
Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application
Fierce Biotech
Santhera Pharmaceuticals
clinical trials
Duchenne Muscular Dystrophy
idebenone
Flag link:
